Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas

Clinical trial NCT04952584 · WITHDRAWN

Trial details

NCT number: NCT04952584
Sponsor: Baylor College of Medicine
Status: WITHDRAWN
Phase: Phase 1
Study type: INTERVENTIONAL

Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type Classical Hodgkin Lymphoma

Start date: 2024-03-01
Primary completion: 2025-06-01
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.